{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:02:40Z","timestamp":1772798560815,"version":"3.50.1"},"reference-count":19,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Institut National Du Cancer, Direction G\u00e9n\u00e9rale de l'offre de soins","award":["- NetSARC+ https:\/\/netsarc.sarcomabcb.org\/"],"award-info":[{"award-number":["- NetSARC+ https:\/\/netsarc.sarcomabcb.org\/"]}]},{"name":"Institut National Du Cancer, Direction G\u00e9n\u00e9rale de l'offre de soins","award":["RREPS https:\/\/rreps.sarcomabcb.org\/"],"award-info":[{"award-number":["RREPS https:\/\/rreps.sarcomabcb.org\/"]}]},{"name":"Institut National du Cancer, Direction G\u00e9n\u00e9rale de l\u2019Offre de Soins","award":["RESOS sarcomes osseux https:\/\/smex-ctp.trendmicro.com:443\/wis\/clicktime\/v1\/query?url=http%3a%2f%2fwww.infosarcomes.org%2fles%2dreseaux%2dnetsarc%2det%2dresos&umid=00863701-ad69-4524-9a16-730de25c5587&auth=88b027512158546030ba1422e012c48ffde03353-ed5dbba3f80d37e0001a8959b45ac64ed4eed50b"],"award-info":[{"award-number":["RESOS sarcomes osseux https:\/\/smex-ctp.trendmicro.com:443\/wis\/clicktime\/v1\/query?url=http%3a%2f%2fwww.infosarcomes.org%2fles%2dreseaux%2dnetsarc%2det%2dresos&umid=00863701-ad69-4524-9a16-730de25c5587&auth=88b027512158546030ba1422e012c48ffde03353-ed5dbba3f80d37e0001a8959b45ac64ed4eed50b"]}]},{"name":"Institut National du Cancer, Direction G\u00e9n\u00e9rale de l\u2019Offre de Soins","award":["INCA-DGOS-INSERM 12563 : Site de recherche int\u00e9gr\u00e9 en canc\u00e9rologie LYRICAN INCa_4664 https:\/\/smex-ctp.trendmicro.com:443\/wis\/clicktime\/v1\/query?url=https%3a%2f%2fwww.cancer%2dlyrican.fr&umid=00863701-ad69-4524-9a16-730de25c5587&auth=88b027512158546030ba1422e012c48ffde03353-39b1f346f522137c25e1fc7c976f1fed6eaba332"],"award-info":[{"award-number":["INCA-DGOS-INSERM 12563 : Site de recherche int\u00e9gr\u00e9 en canc\u00e9rologie LYRICAN INCa_4664 https:\/\/smex-ctp.trendmicro.com:443\/wis\/clicktime\/v1\/query?url=https%3a%2f%2fwww.cancer%2dlyrican.fr&umid=00863701-ad69-4524-9a16-730de25c5587&auth=88b027512158546030ba1422e012c48ffde03353-39b1f346f522137c25e1fc7c976f1fed6eaba332"]}]},{"name":"Institut National du Cancer, Direction G\u00e9n\u00e9rale de l\u2019Offre de Soins","award":["INCA InterSARC https:\/\/smex-ctp.trendmicro.com:443\/wis\/clicktime\/v1\/query?url=http%3a%2f%2fwww.infosarcomes.org%2fintersarc&umid=00863701-ad69-4524-9a16-730de25c5587&auth=88b027512158546030ba1422e012c48ffde03353-69c9a1ec049ea04469b14f14a26569e76ae3aa2d"],"award-info":[{"award-number":["INCA InterSARC https:\/\/smex-ctp.trendmicro.com:443\/wis\/clicktime\/v1\/query?url=http%3a%2f%2fwww.infosarcomes.org%2fintersarc&umid=00863701-ad69-4524-9a16-730de25c5587&auth=88b027512158546030ba1422e012c48ffde03353-69c9a1ec049ea04469b14f14a26569e76ae3aa2d"]}]},{"DOI":"10.13039\/100011199","name":"FP7 Ideas: European Research Council","doi-asserted-by":"publisher","award":["Eurosarc (FP7-278742) http:\/\/eurosarc.eu\/eurosarc\/general-objectives\/"],"award-info":[{"award-number":["Eurosarc (FP7-278742) http:\/\/eurosarc.eu\/eurosarc\/general-objectives\/"]}],"id":[{"id":"10.13039\/100011199","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Projets Investissements d'Avenir","award":["Laboratoire d\u2019excellence (LabEx) DEvweCAN (ANR-10-LABX-0061) \u00ab Cancer, D\u00e9veloppement, th\u00e9rapies cibl\u00e9es \u00bb http:\/\/devwecan.universite-lyon.fr\/"],"award-info":[{"award-number":["Laboratoire d\u2019excellence (LabEx) DEvweCAN (ANR-10-LABX-0061) \u00ab Cancer, D\u00e9veloppement, th\u00e9rapies cibl\u00e9es \u00bb http:\/\/devwecan.universite-lyon.fr\/"]}]},{"name":"European Reference Networks for adult rare solid cancers","award":["EURACAN (EC 739521) European Reference Networks (ERNs) for adult rare solid cancers http:\/\/euracan.ern-net.eu\/"],"award-info":[{"award-number":["EURACAN (EC 739521) European Reference Networks (ERNs) for adult rare solid cancers http:\/\/euracan.ern-net.eu\/"]}]},{"name":"Institut Convergence Fran\u00e7ois Rabelais","award":["Projet PLAsCAN (Pr\u00e9venir la plasticit\u00e9 et l\u2019adaptabilit\u00e9 tumorale : vers la nouvelle g\u00e9n\u00e9ration de m\u00e9decine personnalis\u00e9e) port\u00e9 par l\u2019Universit\u00e9 de Lyon http:\/\/www.crcl.fr\/75-Plasticite-des-cellules-cancereuses.crcl.aspx?language=fr-FR"],"award-info":[{"award-number":["Projet PLAsCAN (Pr\u00e9venir la plasticit\u00e9 et l\u2019adaptabilit\u00e9 tumorale : vers la nouvelle g\u00e9n\u00e9ration de m\u00e9decine personnalis\u00e9e) port\u00e9 par l\u2019Universit\u00e9 de Lyon http:\/\/www.crcl.fr\/75-Plasticite-des-cellules-cancereuses.crcl.aspx?language=fr-FR"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0233046","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T17:50:22Z","timestamp":1589997022000},"page":"e0233046","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT)"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9904-166X","authenticated-orcid":true,"given":"Mehdi","family":"Brahmi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3857-1688","authenticated-orcid":true,"given":"Philippe","family":"Cassier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armelle","family":"Dufresne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Chabaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Karanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Meurgey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0655-6678","authenticated-orcid":true,"given":"Amine","family":"Bouhamama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Gouin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gualter","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Garret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Pierre","family":"Sunyach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5216-538X","authenticated-orcid":true,"given":"Aur\u00e9lien","family":"Dupr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perrine","family":"Marec-Berard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nad\u00e8ge","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Perol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-120X","authenticated-orcid":true,"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"pone.0233046.ref001","first-page":"413","article-title":"Giant cell tumor of tendon sheath, tenosynovial giant cell tumor, and pigmented villonodular synovitis: defining the presentation, surgical therapy and recurrence","volume":"7","author":"RC Martin","year":"2000","journal-title":"Oncol Rep"},{"key":"pone.0233046.ref002","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/01.coc.0000239142.48188.f6","article-title":"Pigmented villonodular synovitis","volume":"29","author":"WM Mendenhall","year":"2006","journal-title":"Am J Clin Oncol"},{"key":"pone.0233046.ref003","first-page":"102","volume-title":"WHO classification of tumours of soft tissue and bone","author":"N. de S. Somerhausen","year":"2013","edition":"4"},{"issue":"2","key":"pone.0233046.ref004","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2014.11.001","article-title":"Tenosynovial giant cell tumour\/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors","volume":"51","author":"E Palmerini","year":"2015","journal-title":"Eur J Cancer"},{"key":"pone.0233046.ref005","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1470-2045(19)30100-7","article-title":"Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study","volume":"20","author":"TGCT Study Group","year":"2019","journal-title":"Lancet Oncol"},{"key":"pone.0233046.ref006","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1073\/pnas.0507321103","article-title":"A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells","volume":"103","author":"RB West","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0233046.ref007","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/PAS.0b013e31802b86f8","article-title":"Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides","volume":"31","author":"JS Cupp","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"pone.0233046.ref008","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/gcc.20501","article-title":"Molecular identification of COL6A3-CSF1 fusion transcripts in tenosynovial giant cell tumors","volume":"47","author":"E Moller","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"pone.0233046.ref009","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/annonc\/mdn033","article-title":"Complete response to imatinib in relapsing pigmented villonodular synovitis\/tenosynovial giant cell tumor (PVNS\/TGCT)","volume":"19","author":"JY Blay","year":"2008","journal-title":"Ann Oncol"},{"key":"pone.0233046.ref010","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/cncr.26409","article-title":"Efficacy of imatinib mesylate for the treatment of locally advanced and\/or metastatic tenosynovial giant cell tumor\/pigmented villonodular synovitis","volume":"118","author":"PA Cassier","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"pone.0233046.ref011","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2045-3329-3-8","article-title":"Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib","volume":"3","author":"S Stacchiotti","year":"2013","journal-title":"Clin Sarcoma Res"},{"key":"pone.0233046.ref012","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S1470-2045(15)00132-1","article-title":"CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study","volume":"16","author":"PA Cassier","year":"2015","journal-title":"Lancet Oncol"},{"key":"pone.0233046.ref013","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1470-2045(18)30143-8","article-title":"Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial","volume":"19","author":"H Gelderblom","year":"2018","journal-title":"Lancet Oncol"},{"key":"pone.0233046.ref014","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1411366","article-title":"Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor","volume":"373","author":"WD Tap","year":"2015","journal-title":"N Engl J Med"},{"key":"pone.0233046.ref015","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): arandomised phase 3 trial","author":"WD Tap","year":"2019","journal-title":"Lancet"},{"issue":"15","key":"pone.0233046.ref016","first-page":"11078","article-title":"A phase I\/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis dPVNS)","volume":"35","author":"KK Sankhala","journal-title":"J Clin Oncol"},{"key":"pone.0233046.ref017","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S1470-2045(15)00388-5","article-title":"The value of research collaborations and consortia in rare cancers","volume":"17","author":"JY Blay","year":"2016","journal-title":"Lancet Oncol"},{"key":"pone.0233046.ref018","first-page":"mdz124","article-title":"Surgery in reference centers improves survival of sarcoma patients: a nationwide study","author":"JY Blay","year":"2019","journal-title":"Ann Oncol"},{"key":"pone.0233046.ref019","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/annonc\/mdy129","article-title":"Complete response to CSF1R inhibitor in a translocation variant of teno-synovial giant cell tumor without genomic alteration of the CSF1 gene","volume":"29","author":"M Brahmi","year":"2018","journal-title":"Ann Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0233046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T17:50:54Z","timestamp":1589997054000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0233046"}},"subtitle":[],"editor":[{"given":"David M.","family":"Loeb","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0233046","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,20]]}}}